The Lektra deal helps the stock rebound sharply from this week's AI-slowdown-driven selloff, which was sparked by several AI executives' public calls for a deliberate pause in frontier model development, a selloff that also pressured semiconductor names including Kulicke and Soffa (NASDAQ:KLIC) and Qorvo …
VISIUM TECHNOLOGIES, INC. (OTC: VISM) rescinded Mr. Pierce’s appointment to its board effective June 30, 2026, ending his status as a director. The board now consists of two directors, while the company said Pierce is not regarded as having served in that capacity.
Barber Daniel sold 25,000 shares of Aquestive Therapeutics (NASDAQ: AQST) on Sep 15, 2026. The transaction involved the company’s President and CEO.
BOURLA ALBERT received 22 derivative securities of PFIZER INC at $27.55 per share on 15 September 2026. The award increased his reported derivative securities position to 783,985. The transaction carried SEC code A, which denotes an award or grant.
Clene Inc. (NASDAQ: CLNN) is offering 1,219,513 shares of common stock at $3.28 per share, targeting approximately $4.0 million in proceeds before expenses. The funds are intended for general corporate purposes, including regulatory work and preparation of a new drug application for CNM-Au8.
AMD (NASDAQ:AMD) shares surged in Thursday's session, rebounding sharply after last week's AI-slowdown-driven selloff, as chip stocks broadly rallied on renewed confidence in AI infrastructure spending. The rebound follows bullish analyst commentary reaffirming that CPU and GPUDemandcontinues to outpace supply, alongside AMD's own AI …
Disc Medicine (NASDAQ: IRON) CEO Quisel John D exercised options for 36,000 shares at $1.01 per share on 15 September 2026. The transaction covered both Disc Medicine shares and derivative securities.
The rally helps the stock recoup ground lost during this week's broader AI infrastructure selloff, which was triggered by AI executives publicly calling for a slowdown in model development and exacerbated by rising Treasury yields following the Federal Reserve's rate hike. Shares had briefly …
Ellipsys Medical, Inc. has an exempt securities offering totaling $10,850,000, with $5,906,665 already sold. The disclosed figures leave $4,943,335 associated with the offering after the reported sales.
The comments, welcomed publicly by Chief Executive Officer Brian Armstrong, are helping stabilize sentiment after the stock plunged more than 10% on Tuesday following the bill's defeat, as investors weigh whether agency-led rulemaking can substitute for the regulatory certainty legislation would have provided.